# A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02345161** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1811 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Triple FF/UMEC/VI
- **DRUG:** Placebo to match FF/UMEC/VI
- **DRUG:** Budesonide/Formoterol
- **DRUG:** Placebo to match Budesonide/Formoterol combination
- **DRUG:** Albuterol/salbutamol

## Key facts

- **NCT ID:** NCT02345161
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-23
- **Primary completion:** 2016-04-01
- **Final completion:** 2016-04-07
- **Target enrollment:** 1811 (ACTUAL)
- **Last updated:** 2018-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02345161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02345161, "A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02345161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*